F2G Ltd (Manchester, UK) is a biopharmaceutical company focusing on the discovery and development of novel drugs for the treatment of life-threatening, systemic fungal diseases. The company has identified a novel pharmacological target that is specific to fungi, particularly the Aspergillus species. The company’s lead drug candidate is the first of a novel class of systemic anti-fungal agents and is currently in clinical development.

Sten Verland, PhD MSc

General Partner

Mobile: +45 24 22 19 69